{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:54Z","timestamp":1790315094132,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>A phase I first-in-human study was conducted to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the anti\u2013insulinlike growth factor 1 receptor (IGF-IR) monoclonal antibody CP-751,871.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>After informed consent and screening, 47 patients with multiple myeloma in relapse or refractory phase were enrolled into 11 dose-escalation cohorts of CP-751,871 at doses from 0.025 to 20 mg\/kg for 4 weeks. Patients with less than a partial response to CP-751,871 treatment were eligible to receive CP-751,871 in combination with oral dexamethasone at the discretion of the investigator. Treatment with CP-751,871 and rapamycin with or without dexamethasone was also offered to patients enrolled in the 10 and 20 mg\/kg cohorts with less than a partial response to initial therapy with single-agent CP-751,871.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No CP-751,871-related dose-limiting toxicities were identified. Plasma CP-751,871 concentrations increased with dose and concentration-time profiles were consistent with those of antibodies with target-mediated disposition. Importantly, CP-751,871 administration led to a decrease in granulocyte IGF-IR expression and serum insulinlike growth factor 1 accumulation at high doses, suggesting systemic IGF-IR inhibition. Tumor response was assessed according to the European Group for Blood and Marrow Transplantation criteria. Nine responses were reported in 27 patients treated with CP-751,871 in combination with dexamethasone. Of interest, two of the patients with a partial response were progressing from dexamethasone treatment at study entry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.15.9319","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T01:10:48Z","timestamp":1210641048000},"page":"3196-3203","source":"Crossref","is-referenced-by-count":132,"title":["Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti\u2013Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma"],"prefix":"10.1200","volume":"26","author":[{"given":"Martha Q.","family":"Lacy","sequence":"first","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luisa","family":"Paccagnella","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Melvin","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Yin","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Sharma","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Enriquez Sarano","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollak","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gualberto","sequence":"additional","affiliation":[{"name":"From the Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN; H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; Mayo Clinic, Division of Hematology, Scottsdale, AZ; Pfizer Global Research & Development, New London, CT; St Vincent's Comprehensive Cancer Center, New York, NY; Dana Farber Cancer Institute Boston, MA; and the McGill University and Lady Davis Research Institute, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Bataille R, Robillard N, Avet-Loiseau H, et al: CD221 (IGF-IR) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 90:706,2005-707,"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403997"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1406"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000037895"},{"key":"R5","unstructured":"Freund GG, Kulas DT, Way BA, et al: Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54:3179,1994-3185,"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00050-9"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250"},{"key":"R8","unstructured":"Li W, Hyun T, Heller M, et al: Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 60:3909,2000-3915,"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Freund GG, Kulas DT, Mooney RA: Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151:1811,1993-1820,","DOI":"10.4049\/jimmunol.151.4.1811"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Jelinek DF, Witzig TE, Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159:487,1997-496,","DOI":"10.4049\/jimmunol.159.1.487"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1724"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.8.4953"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.1999.11746445"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.592708.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02364.x"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2856"},{"key":"R17","unstructured":"Asosingh K, Gunthert U, Bakkus MH, et al: In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 60:3096,2000-3104,"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.235"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208844"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.9.3546.bloodjournal8893546"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00625-1"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114315"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21653"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0196-9"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0293"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1070"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"R29","unstructured":"Jagannath S, Richardson PG, Barlogie B, et al: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929,2006-934,"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1118"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.904"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2447"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1543"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0068"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Gualberto A, Alsina M, Lacy MQ, et al: Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma. J Clin Oncol 23:203s,2005, (abstr 3048)","DOI":"10.1200\/jco.2005.23.16_suppl.3048"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707163170303"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.2337\/diab.45.1.91"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.08.006"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1556"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(82)81081-8"},{"key":"R43","unstructured":"Aron DC: Insulin-like growth factor I and erythropoiesis. Biofactors 3:211,1992-216,"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02724.x"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030518"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.12.041"},{"key":"R47","unstructured":"Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912,2003-8921,"},{"key":"R48","unstructured":"Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073,2003-5083,"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010107"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"R51","unstructured":"Ogawa M, Nishiura T, Oritani K, et al: Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 60:4262,2000-4269,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.15.9319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:31:13Z","timestamp":1684398673000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.15.9319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":51,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2008,7,1]]}},"alternative-id":["10.1200\/JCO.2007.15.9319"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.15.9319","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}